Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor

Biochemical and Biophysical Research Communications

Volumn 448, Issue 2, 2014, Pages 212-217

  Yan, Hao ^a   Wu, Mengyao ^a   Yuan, Yan ^a   Wang, Zack Z ^b   Jiang, Hua ^c   Chen, Tong ^a  

^a FUDAN UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

BAFF; LPS; Mesenchymal stem cell; Pro inflammatory; TLR4

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYINOSINIC POLYCYTIDYLIC ACID; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; ZYMOSAN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

MURINAE;

BAFF; LPS; MESENCHYMAL STEM CELL; PRO-INFLAMMATORY; TLR4;

ADULT; ANIMALS; B-CELL ACTIVATING FACTOR; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; LIPOPOLYSACCHARIDES; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MIDDLE AGED; NF-KAPPA B; POLY I-C; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; ZYMOSAN;

EID: 84901589224     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.097     Document Type: Article

References (26)

1. M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, and D.R. Marshak Multilineage potential of adult human mesenchymal stem cells Science 284 1999 143 147
2. M. Krampera, L. Cosmi, R. Angeli, A. Pasini, F. Liotta, A. Andreini, V. Santarlasci, B. Mazzinghi, G. Pizzolo, F. Vinante, P. Romagnani, E. Maggi, S. Romagnani, and F. Annunziato Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells Stem Cells 24 2006 386 398
3. K. English, F.P. Barry, C.P. Field-Corbett, and B.P. Mahon IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells Immunol. Lett. 110 2007 91 100
4. J.M. Ryan, F. Barry, J.M. Murphy, and B.P. Mahon Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells Clin. Exp. Immunol. 149 2007 353 363
5. S. Aggarwal, and M.F. Pittenger Human mesenchymal stem cells modulate allogeneic immune cell responses Blood 105 2005 1815 1822
6. R.H. Lee, A.A. Pulin, M.J. Seo, D.J. Kota, J. Ylostalo, B.L. Larson, L. Semprun-Prieto, P. Delafontaine, and D.J. Prockop Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 Cell Stem Cell 5 2009 54 63
7. K. Sato, K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, and K. Ozawa Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells Blood 109 2007 228 234
8. K. Akiyama, C. Chen, D. Wang, X. Xu, C. Qu, T. Yamaza, T. Cai, W. Chen, L. Sun, and S. Shi Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis Cell Stem Cell 10 2012 544 555
9. A. Augello, R. Tasso, S.M. Negrini, A. Amateis, F. Indiveri, R. Cancedda, and G. Pennesi Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway Eur. J. Immunol. 35 2005 1482 1490
10. M. Sioud New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins Scand. J. Immunol. 73 2011 79 84
11. Y.P. Li, S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, O. Hequet, Y. Bertrand, J.P. Ou-Yang, J.F. Stoltz, P. Miossec, and A. Eljaafari Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway J. Immunol. 180 2008 1598 1608
12. B. Beutler Inferences, questions and possibilities in Toll-like receptor signalling Nature 430 2004 257 263
13. O. DelaRosa, and E. Lombardo Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential Mediators Inflamm. 2010 2010 865601
14. F. Liotta, R. Angeli, L. Cosmi, L. Fili, C. Manuelli, F. Frosali, B. Mazzinghi, L. Maggi, A. Pasini, V. Lisi, V. Santarlasci, L. Consoloni, M.L. Angelotti, P. Romagnani, P. Parronchi, M. Krampera, E. Maggi, S. Romagnani, and F. Annunziato Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling Stem Cells 26 2008 279 289
15. S.L. Tomchuck, K.J. Zwezdaryk, S.B. Coffelt, R.S. Waterman, E.S. Danka, and A.B. Scandurro Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses Stem Cells 26 2008 99 107
16. I. Rasmusson, K. Le Blanc, B. Sundberg, and O. Ringden Mesenchymal stem cells stimulate antibody secretion in human B cells Scand. J. Immunol. 65 2007 336 343
17. C. Pontikoglou, M.C. Kastrinaki, M. Klaus, C. Kalpadakis, P. Katonis, K. Alpantaki, G.A. Pangalis, and H.A. Papadaki Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia Stem Cells Dev. 22 2013 1329 1341
18. F. Loder, B. Mutschler, R.J. Ray, C.J. Paige, P. Sideras, R. Torres, M.C. Lamers, and R. Carsetti B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals J. Exp. Med. 190 1999 75 89
19. H. Wang, T. Chen, T. Ding, P. Zhu, X. Xu, L. Yu, and Y. Xie Adipogenic differentiation alters the immunoregulatory property of mesenchymal stem cells through BAFF secretion Hematology 16 2011 313 323
20. E. Lombardo, O. DelaRosa, P. Mancheno-Corvo, R. Menta, C. Ramirez, and D. Buscher Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential Tissue Eng. Part A 15 2009 1579 1589
21. M. Pevsner-Fischer, V. Morad, M. Cohen-Sfady, L. Rousso-Noori, A. Zanin-Zhorov, S. Cohen, I.R. Cohen, and D. Zipori Toll-like receptors and their ligands control mesenchymal stem cell functions Blood 109 2007 1422 1432
22. R.S. Waterman, S.L. Tomchuck, S.L. Henkle, and A.M. Betancourt A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype PLoS One 5 2010 e10088
23. W. Li, G. Ren, Y. Huang, J. Su, Y. Han, J. Li, X. Chen, K. Cao, Q. Chen, P. Shou, L. Zhang, Z.R. Yuan, A.I. Roberts, S. Shi, A.D. Le, and Y. Shi Mesenchymal stem cells: a double-edged sword in regulating immune responses Cell Death Differ. 19 2012 1505 1513
24. C. Shi, T. Jia, S. Mendez-Ferrer, T.M. Hohl, N.V. Serbina, L. Lipuma, I. Leiner, M.O. Li, P.S. Frenette, and E.G. Pamer Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands Immunity 34 2011 590 601
25. J. Lei, Z. Wang, D. Hui, W. Yu, D. Zhou, W. Xia, C. Chen, Q. Zhang, Z. Wang, Q. Zhang, and A.P. Xiang Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity Cell Immunol. 271 2011 147 156
26. F. Dazzi, and M. Krampera Mesenchymal stem cells and autoimmune diseases Best Pract. Res. Clin. Haematol. 24 2011 49 57